⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787049 | 0.77 | ALDH1A1 (0.32) | — | |
| SCHEMBL940899 | 0.71 | — | — | |
| SCHEMBL7021 | 0.69 | — | — | |
| SCHEMBL6852244 | 0.68 | CCR1 (0.35) | — | |
| SCHEMBL7260807 | 0.67 | IDO1 (0.40) | — | |
| SCHEMBL935566 | 0.67 | — | — | |
| SCHEMBL935229 | 0.67 | — | — | |
| SCHEMBL14859078 | 0.67 | — | — | |
| SCHEMBL392829 | 0.67 | — | — | |
| SCHEMBL935675 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622944-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250230318-A1 | REAGENTS FOR FLUORESCENT, UV, AND MS LABELING OF O-GLYCANS AND METHODS OF MAKING AND USING THEM | AGILENT TECHNOLOGIES, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250161471-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | TIAN FENG (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250002595-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX INC (US) | 2025-01-02 | — | — | US | disclosed |
| EP-4482914-A1 | REAGENTS FOR FLUORESCENT, UV, AND MS LABELING OF O-GLYCANS, AND METHODS OF MAKING AND USING THEM | Agilent Technologies, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024215515-A1 | DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024178360-A2 | AURISTATIN ANALOGS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20240269164-A1 | A SOLID-GAS REACTION TO GENERATE NITROXYL (HNO) IN THE GAS PHASE | THE JOHNS HOPKINS UNIVERSITY | 2024-08-15 | — | — | US | disclosed |
| EP-4406612-A2 | ANTI-CD70 ANTIBODY DRUG CONJUGATES | Ambrx, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-11459392-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11420999-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220226488-A1 | COMPOSITIONS CONTAINING, METHODS AND USES OF ANTIBODY-TLR AGONIST CONJUGATES | AMBRX, INC. | 2022-07-21 | — | — | US | disclosed |
| WO-2022040596-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | AMBRX,INC. (US) | 2022-02-03 | — | — | US | disclosed |
| EP-1259506-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6387911-B1 | Pyrazinone thrombin inhibitors | MERCK & CO., INC. | 2002-05-14 | — | — | US | disclosed |
| EP-1189899-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001038323-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000075134-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-12-14 | — | — | WO | disclosed |